Immunological Medicine最新文献_第8页

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies. 探讨Janus激酶(JAK)在特应性皮炎中的作用:分子机制和治疗策略的综述。

IF 4.4

Immunological Medicine Pub Date : 2023-09-01 DOI: 10.1080/25785826.2023.2214324

Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima

{"title":"Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies.","authors":"Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima","doi":"10.1080/25785826.2023.2214324","DOIUrl":"https://doi.org/10.1080/25785826.2023.2214324","url":null,"abstract":"Recent studies have demonstrated that Janus kinase (JAK) plays a crucial role in signal transduction by directly affecting various cytokine receptors involved in inflammatory diseases such as atopic dermatitis (AD). Large-scale clinical trials on AD utilizing JAK inhibitors and biologic reagents, such as dupilumab, which targets the IL-4Rα receptor subunit of the Th2 cytokines IL-4 and IL-13, have yielded highly favorable results in comparison to traditional therapies. This indicates that therapeutic strategies based on molecular biology are efficacious in clinical settings. However, in September 2021, the U.S. Food and Drug Administration (FDA) indicated that tofacitinib, a JAK inhibitor, may carry various risks, including severe heart disease. Similar concerns have been raised for other JAK inhibitors, and further safety evaluations are underway. Thus, human biology involving JAKs appeared more complicated than we expected. In this article, we provide an overview of the molecular mechanisms of AD and examine the molecular targeting drugs for AD from the perspective of JAK-related biology.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":"46 3","pages":"112-120"},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9919927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment. 了解个别Janus激酶抑制剂在溃疡性结肠炎治疗中的疗效，以供未来在炎症性肠病治疗中定位。

IF 4.4

Immunological Medicine Pub Date : 2023-09-01 Epub Date: 2023-04-10 DOI: 10.1080/25785826.2023.2195522

Hiroshi Nakase

引用次数: 0

Recent progress of JAK inhibitors for hematological disorders. JAK抑制剂治疗血液病的最新进展。

IF 4.4

Immunological Medicine Pub Date : 2023-09-01 Epub Date: 2022-10-28 DOI: 10.1080/25785826.2022.2139317

Keita Kirito

{"title":"Recent progress of JAK inhibitors for hematological disorders.","authors":"Keita Kirito","doi":"10.1080/25785826.2022.2139317","DOIUrl":"10.1080/25785826.2022.2139317","url":null,"abstract":"Abstract JAK inhibitors are important therapeutic options for hematological disorders, especially myeloproliferative neoplasms. Ruxolitinib, the first JAK inhibitor approved for clinical use, improves splenomegaly and ameliorates constitutional symptoms in both myelofibrosis and polycythemia vera patients. Ruxolitinib is also useful for controlling hematocrit levels in polycythemia vera patients who were inadequately controlled by conventional therapies. Furthermore, pretransplantation use of ruxolitinib may improve the outcome of allo-hematopoietic stem cell transplantation in myelofibrosis. In contrast to these clinical merits, evidence of the disease-modifying action of ruxolitinib, i.e., reduction of malignant clones or improvement of bone marrow pathological findings, is limited, and many myelofibrosis patients discontinued ruxolitinib due to adverse events or disease progression. To overcome these limitations of ruxolitinib, several new types of JAK inhibitors have been developed. Among them, fedratinib was proven to provide clinical merits even in patients who were resistant or intolerant to ruxolitinib. Pacritinib and momelotinib have shown merits for myelofibrosis patients with thrombocytopenia or anemia, respectively. In addition to treatment for myeloproliferative neoplasms, recent studies have demonstrated that JAK inhibitors are novel and attractive therapeutic options for corticosteroid-refractory acute as well as chronic graft versus host disease.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":"46 3","pages":"131-142"},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9953916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

JAK inhibitors in rheumatology. 风湿病抑制剂。

IF 4.4

Immunological Medicine Pub Date : 2023-09-01 Epub Date: 2023-02-06 DOI: 10.1080/25785826.2023.2172808

Kunihiro Yamaoka, Kenji Oku

引用次数: 3

Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination. sars - cov - 2mrna疫苗接种后伴噬淋巴组织细胞增多的补体性荨麻疹血管炎病例。

IF 4.4

Immunological Medicine Pub Date : 2023-06-01 DOI: 10.1080/25785826.2023.2193286

Narumichi Iwamura, Katsumi Eguchi, Tomohiro Koga, Kanako Tsutsumi, Takeshi Araki, Toshiyuki Aramaki, Ayuko Takatani, Kaoru Terada, Yukitaka Ueki

{"title":"Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination.","authors":"Narumichi Iwamura, Katsumi Eguchi, Tomohiro Koga, Kanako Tsutsumi, Takeshi Araki, Toshiyuki Aramaki, Ayuko Takatani, Kaoru Terada, Yukitaka Ueki","doi":"10.1080/25785826.2023.2193286","DOIUrl":"https://doi.org/10.1080/25785826.2023.2193286","url":null,"abstract":"A 61-year-old man with no previous record of autoimmune disease developed fever, polyarthralgia, purpura, and urticaria-like rash 2 weeks after the first dose of the Moderna mRNA-1273 vaccine, and symptoms deteriorated following the second dose. He presented reduced erythrocyte and platelet counts, hyperferritinemia, high sIL-2R levels, and severe hypocomplementemia. We diagnosed hypocomplementemic urticarial vasculitis (HUVS), and his symptoms as well as laboratory findings improved following treatment with mPSL 1000 mg/day for 3 days and PSL 40 mg/day. Twelve weeks following treatment initiation, the patient relapsed with fever, sore throat, pancytopenia, and hyperferritinemia when the PSL dose was reduced to 12.5 mg/day. Bone marrow biopsy and MRI presented fatty marrow and hemophagocytosis. The patient's blood cells started recovering using ATG + CsA + EPAG therapy for hemophagocytic lymphohistiocytosis (HLH). This is the first case report of HUVS and HLH following SARS-CoV-2 mRNA vaccination. It is presumed that SARS-CoV-2 mRNA vaccine can induce the excessive production of certain types of cytokines, such as TNF-α, IL-1, IL-4, IL-5, IL-6, and IL-17 as a consequence of IL-6 Amplification (IL-6 Amp). SARS-CoV-2 mRNA-vaccines can cause disruption of immune homeostasis in healthy individuals. An extremely rare disease of HUVS complicated by HLH can be developed as a consequence.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":"46 2","pages":"97-107"},"PeriodicalIF":4.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The association between PD-1 gene polymorphisms and susceptibility to multiple sclerosis. PD-1基因多态性与多发性硬化易感性之间的关系。

IF 4.4

Immunological Medicine Pub Date : 2023-06-01 DOI: 10.1080/25785826.2022.2137967

Nasrin Hassani, Arash Salmaninejad, Saeed Aslani, Eskandar Kamali-Sarvestani, Mahmood Vessal

引用次数: 2

Epigenetic control of skin immunity. 皮肤免疫的表观遗传控制。

IF 4.4

Immunological Medicine Pub Date : 2023-06-01 DOI: 10.1080/25785826.2023.2170087

Sayaka Shibata

引用次数: 0

Metastatic pulmonary pleomorphic carcinoma replaced by a granulomatous lesion after spontaneous regression and PD-1 blockade-induced regression: can epithelioid granuloma be a histological hallmark of cancer immunity? 转移性肺多形性癌在自发消退和PD-1阻断诱导消退后被肉芽肿病变所取代:上皮样肉芽肿可以作为癌症免疫的组织学标志吗?

IF 4.4

Immunological Medicine Pub Date : 2023-06-01 DOI: 10.1080/25785826.2023.2193283

Naoki Shijubou, Yuichiro Asai, Michiko Hosaka, Keiko Segawa, Terufumi Kubo, Masahiro Miyajima, Tomohide Tsukahara, Yoshihiko Hirohashi, Takayuki Kanaseki, Kenji Murata, Atsushi Watanabe, Tadashi Hasegawa, Hirofumi Chiba, Toshihiko Torigoe

{"title":"Metastatic pulmonary pleomorphic carcinoma replaced by a granulomatous lesion after spontaneous regression and PD-1 blockade-induced regression: can epithelioid granuloma be a histological hallmark of cancer immunity?","authors":"Naoki Shijubou, Yuichiro Asai, Michiko Hosaka, Keiko Segawa, Terufumi Kubo, Masahiro Miyajima, Tomohide Tsukahara, Yoshihiko Hirohashi, Takayuki Kanaseki, Kenji Murata, Atsushi Watanabe, Tadashi Hasegawa, Hirofumi Chiba, Toshihiko Torigoe","doi":"10.1080/25785826.2023.2193283","DOIUrl":"https://doi.org/10.1080/25785826.2023.2193283","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) for various types of malignancy, including non-small-cell lung cancer, have improved prognosis in some cases. Granuloma formation after ICI administration suggests a tumor antigen-specific cytotoxic T cell response with abundant interferon-gamma production, which can be used to estimate the curative effect of ICIs. In this report, we present a case with a resected lung lesion, clinically suspected to be lung cancer, that consisted of a granulomatous lesion. A tumor was also found in the duodenum that was presumed to be derived from the pulmonary pleomorphic carcinoma. Duodenal tumor cells highly expressed PD-L1, suggesting PD-1/PD-L1 axis-mediated immune escape. As expected, pembrolizumab induced a complete response for the duodenal lesion. Interestingly, in histopathological analysis, the duodenal lesion was also replaced by an epithelial granuloma and multinucleated giant cells. We conclude that autoimmunity regressed the untreated primary lung lesion spontaneously, while the metastatic duodenal lesion responded to PD-1 blockade. Tumor-associated epithelioid granulomas, even before ICI administration, may be an important pathological finding indicating an immune response with interferon-gamma production by cytotoxic T cells to the tumor.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":"46 2","pages":"93-96"},"PeriodicalIF":4.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smoking and younger age at onset in anti-acetylcholine receptor antibody-positive myasthenia gravis. 抗乙酰胆碱受体抗体阳性重症肌无力的发病年龄与吸烟有关。

IF 4.4

Immunological Medicine Pub Date : 2023-06-01 DOI: 10.1080/25785826.2022.2143077

Yusei Miyazaki, Ken Sakushima, Masaaki Niino, Eri Takahashi, Kei Oiwa, Ryoji Naganuma, Itaru Amino, Sachiko Akimoto, Naoya Minami, Ichiro Yabe, Seiji Kikuchi

{"title":"Smoking and younger age at onset in anti-acetylcholine receptor antibody-positive myasthenia gravis.","authors":"Yusei Miyazaki, Ken Sakushima, Masaaki Niino, Eri Takahashi, Kei Oiwa, Ryoji Naganuma, Itaru Amino, Sachiko Akimoto, Naoya Minami, Ichiro Yabe, Seiji Kikuchi","doi":"10.1080/25785826.2022.2143077","DOIUrl":"https://doi.org/10.1080/25785826.2022.2143077","url":null,"abstract":"Smoking is a known risk factor for the development and progression of several autoimmune diseases. Previous studies have pointed out the association of smoking with the development and worsening of symptoms in myasthenia gravis (MG), but further investigation is necessary to confirm this association. Smoking history was investigated in a cross-sectional study of 139 patients with anti-acetylcholine receptor antibody-positive MG, and the association of smoking history with the age at the onset of MG was analyzed. Patients who had been smoking at the onset of MG were significantly younger compared with those who had never smoked or had quit before the onset of MG. A linear regression analysis adjusting for sex and the presence/absence of thymoma showed a significant association between smoking at onset and younger age at onset (regression coefficient -9.05; 95% confidence interval, -17.6, -0.51; p = 0.039). Among patients with smoking exposure within 10 years prior to or at the onset of MG, women were significantly younger at the onset of MG compared with men. Our results suggest that smoking is an independent risk factor for the earlier development of anti-acetylcholine receptor antibody-positive MG and further support the putative link between smoking and MG.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":"46 2","pages":"77-83"},"PeriodicalIF":4.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9470218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort. 基线红细胞沉降水平预测托珠单抗对放射学进展的长期抑制:KURAMA队列。

IF 4.4

Immunological Medicine Pub Date : 2023-06-01 DOI: 10.1080/25785826.2023.2170384

Ryu Watanabe, Kosaku Murakami, Toshimitsu Fujisaki, Hiromu Ito, Koichi Murata, Wataru Yamamoto, Takayuki Fujii, Hideo Onizawa, Akira Onishi, Masao Tanaka, Akio Morinobu, Motomu Hashimoto

{"title":"Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort.","authors":"Ryu Watanabe, Kosaku Murakami, Toshimitsu Fujisaki, Hiromu Ito, Koichi Murata, Wataru Yamamoto, Takayuki Fujii, Hideo Onizawa, Akira Onishi, Masao Tanaka, Akio Morinobu, Motomu Hashimoto","doi":"10.1080/25785826.2023.2170384","DOIUrl":"https://doi.org/10.1080/25785826.2023.2170384","url":null,"abstract":"The short-term effect of tocilizumab (TCZ) on the radiographic progression of rheumatoid arthritis has been reported; however, reports on its long-term effects are scarce. In this study, we aimed to evaluate its long-term effects on joint destruction in patients who had been treated with TCZ for at least two years and for whom X-rays were available. Radiographic progression was evaluated with modified Total Sharp Score (mTSS), and structural remission was defined as the mean annual change in mTSS ≤0.5. Of the 59 patients included in this study (median age, 62 years; female, 81.4%), 34 patients (57.6%) achieved structural remission. Patients who achieved structural remission were relatively younger (59 years vs. 64 years, p = .06), had relatively higher proportion of anti-citrullinated protein antibody positivity (91.2% vs. 72.0%, p = .08), relatively lower C-reactive protein level (0.6 mg/dL vs. 2.2 mg/dL, p = .05), and significantly lower erythrocyte sedimentation rate (ESR) level (28.0 mm/h vs 65.5 mm/h, p = .003) than those who did not. Multivariate logistic regression analysis demonstrated that the baseline ESR level was significantly associated with structural remission (odds ratio, 0.98; 95% confidence interval: 0.96-0.99, p = .049). The baseline ESR level is a critical determinant of the long-term effect of TCZ on joint destruction.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":"46 2","pages":"84-92"},"PeriodicalIF":4.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9476557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1